Price erosion in US generics
While current price erosion is neutral, increased competition could pressure margins in oral solids and injectables.
medium · management_commentary
Aurobindo Pharma Limited — Q2 FY24
Aurobindo Pharma delivered a strong Q2 FY24 with revenue of INR 7,219 crore (+25.8% YoY), EBITDA of INR 1,403 crore (+67.7% YoY), and PAT of INR 752 crore (+83.6% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Execution risk in new plant ramp-ups
Pen-G, China, and biosimilar plants face commissioning delays; revenue contribution may shift to FY26.
medium · management_commentaryDepreciation and impairment charges
Higher depreciation due to impairment provisions may persist, impacting reported profitability.
low · data_observationDependence on gRevlimid for margin target
Analyst questioned if 20% margin guidance includes gRevlimid; management confirmed, but any volume/pricing shortfall could miss target.
medium · analyst_question